Octreotide in hepatorenal syndrome

Octreotide may be used in combination with midodrine and albumin  to minimize peripheral vasodilation in the hepatorenal syndrome. In return, by increasing systemic vascular resistance, shunting of blood get reduced and it improves renal perfusion. Study has showed that treatment with octreotide, midodrine, and albumin were independently associated with improved survival. Also, Renal function was significantly improved at 1 month.

Skagen C, Einstein M, Lucey MR, Said A (Feb 2009). "Combination Treatment With Octreotide, Midodrine, and Albumin Improves Survival in Patients With Type 1 and Type 2 Hepatorenal Syndrome.". J Clin Gastroenterol. 43 (7): 680–5., Link: http://www.ncbi.nlm.nih.gov/pubmed/19238094